Spark Therapeutics, Inc. (NASDAQ:ONCE) had its target price upped by investment analysts at BMO Capital Markets from $69.00 to $89.00 in a research report issued to clients and investors on Wednesday. The firm currently has an “outperform” rating on the biotechnology company’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 15.64% from the company’s current price.
A number of other analysts have also commented on ONCE. Sanford C. Bernstein began coverage on shares of Spark Therapeutics in a research note on Thursday, July 27th. They issued an “outperform” rating and a $87.00 price target for the company. ValuEngine upgraded shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $60.00 to $100.00 in a research note on Wednesday. Jefferies Group LLC reiterated a “buy” rating and issued a $85.00 price target on shares of Spark Therapeutics in a research note on Monday, July 24th. Finally, Cantor Fitzgerald set a $94.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $82.27.
Spark Therapeutics (ONCE) traded up 0.14% on Wednesday, hitting $76.96. 2,519,357 shares of the stock were exchanged. The company has a 50-day moving average of $63.15 and a 200-day moving average of $58.70. The stock’s market cap is $2.38 billion. Spark Therapeutics has a 12 month low of $35.07 and a 12 month high of $78.08.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. Spark Therapeutics had a negative return on equity of 55.25% and a negative net margin of 962.72%. The company had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. During the same quarter in the prior year, the firm earned ($1.04) earnings per share. The business’s revenue was up 14.7% compared to the same quarter last year. On average, equities analysts predict that Spark Therapeutics will post ($6.80) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Spark Therapeutics, Inc. (NASDAQ:ONCE) PT Raised to $89.00” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2017/08/04/spark-therapeutics-inc-nasdaqonce-pt-raised-to-89-00.html.
In related news, General Counsel Barge Joseph La sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $55.00, for a total transaction of $275,000.00. Following the completion of the sale, the general counsel now directly owns 9,567 shares in the company, valued at $526,185. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Katherine A. High sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the sale, the insider now owns 220,000 shares of the company’s stock, valued at $13,200,000. The disclosure for this sale can be found here. Insiders have sold 314,310 shares of company stock valued at $21,866,838 over the last 90 days. 7.30% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in shares of Spark Therapeutics by 0.9% in the first quarter. FMR LLC now owns 4,656,655 shares of the biotechnology company’s stock valued at $248,386,000 after buying an additional 40,698 shares during the period. BlackRock Inc. increased its position in shares of Spark Therapeutics by 11,332.0% in the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock valued at $98,158,000 after buying an additional 1,824,117 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Spark Therapeutics by 5.2% in the first quarter. Vanguard Group Inc. now owns 1,827,660 shares of the biotechnology company’s stock valued at $97,487,000 after buying an additional 90,686 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Spark Therapeutics by 7.8% in the first quarter. JPMorgan Chase & Co. now owns 1,549,093 shares of the biotechnology company’s stock valued at $82,628,000 after buying an additional 112,596 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Spark Therapeutics by 119.5% in the first quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock valued at $43,140,000 after buying an additional 440,287 shares in the last quarter. Institutional investors own 88.96% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
